St. Jude Reference #SJ-18-0019
Description
Researchers at St. Jude have invented a novel way to expand chimeric antigen receptor (CAR) T cells that work better for gene therapy. These T cells could form the basis of the next generation of CAR therapies that provide sustainable, superior antitumor activity.
Incorporating IL-12 in in vitro culture conditions results in the generation of stem cell memory (Tscm) cells, which possess an enhanced ability to eradicate tumors without reaching exhaustion.
Keywords
cer, immunology, chimeric antigen receptor (CAR), T cell, stem cell memory (Tscm) cells, epigenetic, IL-12, expansion
Granted patents or published applications
Pending PCT, published as WO 2020/012331.
Related scientific references
Knocking out specific gene prevents T-cell exhaustion, boosts CAR T-cell responses
Brooke Prinzing et al, Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity, Science Translational Medicine (2021). DOI: 10.1126/scitranslmed.abh0272
Licensing opportunities
St. Jude is seeking a partner or partners to help develop this for use with therapies. Contact: chad.riggs@stjude.org
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.